Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSE:PTN
- CUSIP: N/A
- Web: www.palatin.com
- Market Cap: $52.5 million
- Outstanding Shares: 137,947,000
- 50 Day Moving Avg: $0.39
- 200 Day Moving Avg: $0.44
- 52 Week Range: $0.29 - $0.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 38.06
- P/E Growth: 0.0000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($0.12) per share
- Price / Book: -3.17
- Average Volume: 2.18 million shs.
- Short Ratio: 4.38
Frequently Asked Questions for Palatin Technologies (NYSE:PTN)
What is Palatin Technologies' stock symbol?
Palatin Technologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "PTN."
How were Palatin Technologies' earnings last quarter?
Palatin Technologies, Inc. (NYSE:PTN) released its earnings results on Thursday, May, 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.12. The firm earned $10.82 million during the quarter, compared to the consensus estimate of $60 million. During the same period in the previous year, the company posted ($0.01) earnings per share. View Palatin Technologies' Earnings History.
Where is Palatin Technologies' stock going? Where will Palatin Technologies' stock price be in 2017?
2 brokers have issued 1 year target prices for Palatin Technologies' stock. Their forecasts range from $0.55 to $6.00. On average, they expect Palatin Technologies' stock price to reach $2.68 in the next twelve months. View Analyst Ratings for Palatin Technologies.
Are investors shorting Palatin Technologies?
Palatin Technologies saw a increase in short interest in May. As of May 15th, there was short interest totalling 10,056,495 shares, an increase of 13.5% from the April 28th total of 8,860,354 shares. Based on an average trading volume of 2,453,264 shares, the short-interest ratio is presently 4.1 days. Currently, 7.6% of the shares of the stock are sold short.
Who are some of Palatin Technologies' key competitors?
Some companies that are related to Palatin Technologies include Verastem (VSTM), KaloBios Pharmaceuticals (KBIO), AdCare Health Systems (ADK), Capricor Therapeutics (CAPR), 3SBio (SSRX), Alexza Pharmaceuticals (ALXA), Allergan plc (WPI), Allergan plc (ACT), Allos Therapeutics (ALTH), AMERIGROUP (AGP), Amgen Rockville (MITI), Amylin Pharmaceuticals LLC (AMLN), Anacor Pharmaceuticals (ANAC), ANI Pharmaceuticals (BPAX), Ardea Biosciences (RDEA), ArthroCare (ARTC), Auxilium Pharmaceuticals (AUXL) and Avanir Pharmaceuticals (AVNR).
Who owns Palatin Technologies stock?
Palatin Technologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.28%), Sphera Funds Management LTD. (2.11%), Sabby Management LLC (1.47%), Geode Capital Management LLC (0.49%), California Public Employees Retirement System (0.35%) and National Asset Management Inc. (0.23%). Company insiders that own Palatin Technologies stock include Joseph Stanley Hull and Robert K Deveer Jr. View Institutional Ownership Trends for Palatin Technologies.
Who bought Palatin Technologies stock? Who is buying Palatin Technologies stock?
Palatin Technologies' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sabby Management LLC and National Asset Management Inc.. Company insiders that have bought Palatin Technologies stock in the last two years include Joseph Stanley Hull and Robert K Deveer Jr. View Insider Buying and Selling for Palatin Technologies.
How do I buy Palatin Technologies stock?
Shares of Palatin Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Palatin Technologies stock cost?
One share of Palatin Technologies stock can currently be purchased for approximately $0.38.
Earnings History for Palatin Technologies (NYSE:PTN)Earnings History by Quarter for Palatin Technologies (NYSE:PTN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/18/2017||Q3 2017||$0.10||($0.02)||$60.00 million||$10.82 million||View||N/A|
|9/21/2015||Q415||($0.06)||($0.09)||$2.05 million||$12.95 million||View||Listen|
|2/13/2015||Q115||$0.01||$0.03||$5.40 million||$4.90 million||View||N/A|
|11/18/2014||Q1 15||$0.04||$0.01||$9.00 million||$4.93 million||View||N/A|
|5/14/2013||Q3 2013||($0.05)||($0.04)||$0.02 million||View||Listen|
Earnings Estimates for Palatin Technologies (NYSE:PTN)
Current Year EPS Consensus Estimate: $-0.0700 EPS
Next Year EPS Consensus Estimate: $0.0100 EPS
Dividend History for Palatin Technologies (NYSE:PTN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Palatin Technologies (NYSE:PTN)Insider Trades by Quarter for Palatin Technologies (NYSE:PTN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/4/2015||Joseph Stanley Hull||Director||Buy||2,500||$0.66||$1,650.00|| |
|10/2/2015||Robert K Deveer Jr||Director||Buy||10,000||$0.82||$8,200.00|| |
|2/26/2014||Bvf Partners L P/Il||Major Shareholder||Sell||540,181||$1.14||$615,806.34|| |
|2/19/2014||Bvf Partners L P/Il||Major Shareholder||Sell||305,966||$1.17||$357,980.22|| |
|3/19/2013||Alan W Dunton||Director||Buy||1,000||$0.58||$580.00|| |
|2/1/2013||Alan W Dunton||Director||Buy||2,000||$0.59||$1,180.00|| |
|1/28/2013||Robert I Taber||Director||Buy||5,000||$0.59||$2,950.00|| |
|12/31/2012||Carl Spana||CEO||Buy||10,000||$0.57||$5,700.00|| |
|12/28/2012||Stephen T Wills||CFO||Buy||10,000||$0.56||$5,600.00|| |
|12/24/2012||Perry B Molinoff||Director||Buy||10,000||$0.61||$6,100.00|| |
|12/14/2012||Robert K Deveer Jr||Director||Buy||21,960||$0.70||$15,372.00|| |
|9/4/2012||Alan W Dunton||Director||Buy||1,000||$0.58||$580.00|| |
Headline Trends for Palatin Technologies (NYSE:PTN)
Latest Headlines for Palatin Technologies (NYSE:PTN)
|Palatin Technologies, Inc. (PTN) Short Interest Update|
www.americanbankingnews.com - May 24 at 6:58 PM
|Palatin Technologies, Inc. (PTN) PT Set at $6.00 by Canaccord Genuity|
www.americanbankingnews.com - May 17 at 7:10 PM
|Palatin Technologies, Inc. (PTN) Announces Earnings Results|
www.americanbankingnews.com - May 17 at 10:02 AM
|Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 ... - PR Newswire (press release)|
www.prnewswire.com - May 17 at 12:05 AM
|Edited Transcript of PTN earnings conference call or presentation 16-May-17 3:00pm GMT|
finance.yahoo.com - May 17 at 12:05 AM
|EARNINGS SUMMARY: Details of Palatin Technologies Inc. Q3 Earnings Report|
www.rttnews.com - May 16 at 7:03 PM
|Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017|
finance.yahoo.com - May 16 at 9:44 AM
|Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017|
finance.yahoo.com - May 11 at 8:27 AM
|Palatin Technologies (PTN) Receives Daily Media Sentiment Score of 0.10|
www.americanbankingnews.com - April 29 at 11:57 PM
|Somewhat Positive Media Coverage Very Likely to Affect Palatin Technologies (PTN) Share Price|
www.americanbankingnews.com - April 26 at 9:34 PM
|Palatin Technologies (PTN) Earns Daily News Impact Rating of 0.17|
www.americanbankingnews.com - April 18 at 12:57 AM
|Short Interest in Palatin Technologies, Inc. (PTN) Increases By 1.2%|
www.americanbankingnews.com - April 11 at 7:36 PM
|Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House|
finance.yahoo.com - March 31 at 7:32 PM
|Canaccord Genuity Reiterates $6.00 Price Target for Palatin Technologies, Inc. (PTN)|
www.americanbankingnews.com - March 26 at 9:46 PM
|Short Interest in Palatin Technologies, Inc. (PTN) Declines By 2.3%|
www.americanbankingnews.com - March 25 at 7:14 AM
|Palatin Technologies (PTN) Reports Methods of Use Patent for Treatment of HSDD in Premenopausal Women - StreetInsider.com|
www.streetinsider.com - March 23 at 12:21 AM
|Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women|
finance.yahoo.com - March 20 at 9:26 AM
|7:31 am Palatin Technologies announces that the USPTO has issued a NOA for U.S. Patent Application Serial Number 14/704,223 for the treatment of hypoactive sexual desire disorder in premenopausal women|
finance.yahoo.com - March 20 at 9:26 AM
|Healthcare Stocks on Investors' Radar -- Delcath Systems, Palatin Technologies, AMAG Pharma, and IDEXX Laboratories|
www.bizjournals.com - March 14 at 10:04 AM
|Short Interest in Palatin Technologies, Inc. (PTN) Grows By 22.0%|
www.americanbankingnews.com - March 9 at 6:30 PM
|AMAG Pharma (AMAG), Palatin (PTN) Announce Rekynda Data Presentations at ISSWSH Meeting|
www.streetinsider.com - February 27 at 4:13 PM
|AMAG, Palatin Say Both Phase 3 RECONNECT Studies Met Co-primary End Points|
www.nasdaq.com - February 27 at 9:41 AM
|AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting|
finance.yahoo.com - February 27 at 9:41 AM
|AMAG Inks $60M Women's Health Drug Deal (AMAG)|
www.investopedia.com - February 16 at 6:59 PM
|PALATIN TECHNOLOGIES INC Financials|
finance.yahoo.com - February 16 at 6:59 PM
|PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - February 10 at 9:45 PM
|EARNINGS SUMMARY: Details of Palatin Technologies Inc. Q2 Earnings Report|
www.rttnews.com - February 10 at 3:11 AM
|Palatin Technologies' (PTN) CEO Carl Spana on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - February 9 at 10:08 PM
|Q2 2017 Palatin Technologies Inc Earnings Release - Before Market Open|
biz.yahoo.com - February 9 at 10:08 PM
|Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017|
finance.yahoo.com - February 9 at 10:08 PM
|PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition|
biz.yahoo.com - February 9 at 10:08 PM
|PALATIN TECHNOLOGIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - February 8 at 9:32 PM
|Palatin Technologies (PTN) Closes License Agreement for Rekynda Rights with AMAG Pharmaceuticals (AMAG)|
www.streetinsider.com - February 3 at 8:14 PM
|Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?|
finance.yahoo.com - February 2 at 9:11 PM
Palatin Technologies (PTN) Chart for Thursday, May, 25, 2017